Gastrointestinal disorders as immune-related adverse events
نویسندگان
چکیده
منابع مشابه
Clinical assessment of immune-related adverse events
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across div...
متن کاملAdverse events after flu vaccination in patients with immune disorders.
In one case, an 89-year-old Chinese Indonesian male with eczema and allergic rhinitis was injected with the seasonal flu vaccine (not the H1N1 influenza vaccine) and a pneumococcus vaccine on 14 November 2009. His eczema was in remission at the time of injection. One week later he developed a skin rash that became progressively more severe, involving both upper limbs (Fig 1), both knees, and hi...
متن کاملImmune-related adverse events during anticancer immunotherapy: Pathogenesis and management
Immunotherapy is one of the most recent systemic treatments to emerge for use in oncology, and is based on the blocking of inhibitory immune checkpoints to potentiate the immune response to cancer. The anti-cytotoxic T lymphocyte-associated antigen-4 antibody ipilimumab and anti-programmed cell death protein 1 antibodies, including nivolumab and pembrolizumab, are currently available and widely...
متن کاملManaging immune-related adverse events to ipilimumab: a nurse's guide.
Ipilimumab is a U.S. Food and Drug Administration-approved novel T-cell potentiator that improves survival in metastatic melanoma. Ipilimumab blocks cytotoxic T-lymphocyte antigen-4, a negative regulator of the immune response, thus promoting T-cell activation and prolonging a patient's antitumor response. However, that action may produce a mechanism-related spectrum of immune-related adverse e...
متن کاملTwo Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, it is unclear how or if nivolumab should be administered to patients after they have experienced a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Exploration of Targeted Anti-tumor Therapy
سال: 2021
ISSN: 2692-3114
DOI: 10.37349/etat.2021.00039